New treatment strategies for advanced-stage gastrointestinal stromal tumours.

Abstract excerpt

When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first recognized as a distinct pathological entity in the 1990s, patients with advanced-stage disease had a very poor prognosis owing to a lack of effective medical therapies. The discovery of KIT mutations as the first and most prevalent drivers of GIST and the subsequent development of the first KIT tyrosine kinase inhibitor...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gastrointestinal Stromal Tumors
• Share to Imatinib Mesylate